Efficacy and safety of biotherapies in the treatment of systemic lupus erythematosus

Allergology and Immunology

This systematic review and meta-analysis aimed to evaluate the efficacy and safety of biotherapies in systemic lupus erythematosus (SLE). A total of 44 studies were included up to May 2021, covering 15 therapeutic classes, 25 biotherapies, and 16,889 patients. The primary endpoints were treatment response index, composite lupus assessment, and renal remission. Four types of biotherapies demonstrated clinical improvement in lupus:

Anti-interferons (anifrolumab, sifalimumab)
Anti-BAFF/BLyS and/or APRIL agents (belimumab, tabalumab, telitacicept)
An anti-CD20 monoclonal antibody (obinutuzumab)
An anti-IL12/IL23 monoclonal antibody (ustekinumab)

For some of these biotherapies, safety was not evaluated.

Source(s) :
Justin Chan et al. Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE). BMC Rheumatol. 2023 Oct 9;7(1):37. ;

Cold and the heart: an underestimated risk for cardiovascular mortality

By Elodie Vaz | Published on March 27, 2026 | 4 min read Card...

Hepatoblastoma: a combined strategy to target resistant forms

By Elodie Vaz | Published on March 27, 2026 | 4 min read Hepa...

Diagnosing infection by breathing: the promise of breath tests

By Elodie Vaz | Published on March 26, 2026 | 4 min read Infe...